Document is current
Any future updates will be listed below
-
Authors
Huang, Hua
Baxter, Amy E.
Zhang, Zhen
Good, Charly R.
Alexander, Katherine A.
Chen, Zeyu
Garcia, Paula A. Agudelo
Samareh, Parisa
Collins, Sierra M.
Glastad, Karl M.
Wang, Lu
Donahue, Gregory
Manne, Sasikanth
Giles, Josephine R.
Shi, Junwei
Berger, Shelley L.
Wherry, E. John
-
Funding
Funding for this research was provided by:
National Institutes of Health (CA232466, CA078831, CA078831)
Rob Kugler American Cancer Society Postdoctoral fellow
Cancer Research Institute -Mark Foundation Fellowship
Celgene
Parker Institute for Cancer Immunotherapy
The Mark Foundation
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 23 April 2025
First Online: 19 May 2025
Declarations
:
: E.J.W. is a member of the Parker Institute for Cancer Immunotherapy. E.J.W. is an advisor for Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, New Limit, Marengo, Pluto Immunotherapeutics, Prox Bio, Related Sciences, Santa Ana Bio, and Synthekine. E.J.W. is a founder of Arsenal Biosciences, Danger Bio, Prox Bio and holds stock in Coherus. J.R.G. is a consultant for Arsenal Biosciences, Cellanome, GVM1, and Seismic Therapeutics. The remaining authors declare no competing interests.
: This study is reported in accordance with ARRIVE guidelines.
